US2023279097A1PendingUtilityA1
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
Est. expiryMay 18, 2038(~11.8 yrs left)· nominal 20-yr term from priority
C07K 16/244G01N 33/483G01N 29/4418C07K 16/249C12Q 1/6883A61K 9/0019A61P 37/06G01N 33/564C07K 2317/21A61K 2039/505C12Q 2600/158C12Q 2600/106G01N 2333/555A61K 2039/545C07K 2317/76C07K 2317/24
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with an anti-IL-12/IL-23p40 antibody.
Claims
exact text as granted — not AI-modified1 . A method for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-interleukin-12/interleukin-23p40 antibody (anti-IL-12/IL-23p40 antibody), the method comprising:
a. determining levels of one or more cytotoxic cell markers in biological samples from the patients, wherein the one or more cytotoxic cell markers is selected from the group consisting of: expression level of one or more cytotoxic cell-associated transcriptional genes and percentage of natural killer cells; b. determining levels of one or more Interferon I (IFN-I) markers in biological samples from the patients, wherein the one or more IFN-I markers is selected from the group consisting of: expression level of one or more Interferon I (IFN-I) inducible genes and expression level of Interferon alpha; c. calculating mean levels of the one or more cytotoxic cell markers and the one or more IFN-I markers in the biological samples from the patients; d. comparing the calculated mean levels to the levels in individual patients for the one or more cytotoxic cell markers and the one or more IFN-I markers; e. determining if individual patients have higher levels or lower levels compared to the calculated mean levels of the one or more cytotoxic cell markers and the one or more IFN-I markers; f. selecting the individual patients from the group consisting of: individual patients with higher levels of the one or more cytotoxic cell markers and higher levels of the one or more IFN-I markers, individual patients with higher levels of the one or more cytotoxic cell markers and lower levels of the one or more IFN-I markers, and individual patients with lower levels of the one or more cytotoxic cell markers and lower levels of the one or more IFN-I markers, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment with an anti-IL-12/IL-23p40 antibody; and, g. treating the selected patients by administering the anti-IL-12/IL-23p40 antibody; wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GPR56, GZMH, GZMK, KLRC3, KLRD1, KLRG1, LOC387895, MYBL1, NKG7, PRF1, TARP, TRGC2, XRRA1, GSTM4, CXCR3, GZMA, and TRGV2; and wherein the one or more IFN-I inducible genes is selected from the group consisting of: BST2, CARD17, CMPK2, DDX58, DDX60, DHX58, EIF2AK2, EPSTI1, FBXO39, HERC5, HERC6, IFIT1, IFIT2, IFIT3, IRF7, LAP3, LOC100133669, OAS3, OASL, OTOF, PLSCR1, RSAD2, RTP4, SAMD9L, SIGLEC1, SPATS2L, TIMM10, USP18, ISG15, IFI27, IFI44, IFI44L, and ZBP1.
2 . The method of claim 1 , wherein the positive response is selected from the group consisting of: a significant improvement in disease activity as determined by a decrease from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥4 (SLE Responder Index-4 (SRI-4) response) at 24 weeks of treatment with the anti-IL-12/IL-23p40 antibody; a statistically significant reduction in the risk of a new British Isles Lupus Assessment Group (BILAG) flare, defined as ≥1 new BILAG A domain score or ≥2 new BILAG B domain score, by week 24 of treatment with the anti-IL-12/IL-23p40 antibody; a statistically significant increase in the proportion of patients with a 50% improvement from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score; and a statistically significant improvement in disease activity as determined by a 50% improvement from baseline joint disease activity by week 24 of treatment with the anti-IL-12/IL-23p40 antibody.
3 . The method of claim 2 , wherein the positive response comprises a significant improvement in disease activity as determined by a decrease from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥4 (SRI-4 response) at 24 weeks of treatment with the anti-IL-12/IL-23p40 antibody.
4 . The method of claim 1 , wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GZMH, GZMK, NKG7 and PRF1; and wherein the one or more IFN-I inducible genes is selected from the group consisting of: BST2, CMPK2, DDX58, DDX60, DHX58, EIF2AK2, EPSTI1, HERC5, IFIT1, IFIT2, IFIT3, IRF7, ISG15, LAP3, OAS3, OASL, PLSCR1, RSAD2, RTP4, SAMD9L, SIGLEC1, TIMM10, USP18 and ZBP1.
5 . The method of claim 1 , wherein the one or more cytotoxic cell-associated transcriptional genes comprise FCRL6, FGFBP2, GNLY, GZMH, NKG7, and PRF1; and the one or more IFN-I inducible genes comprise IFIT3 and RSAD2.
6 . The method of claim 1 , wherein the levels of the one or more cytotoxic cell markers and the one or more IFN-I markers are determined by quantifying RNA transcripts in the biological samples or quantifying protein expression levels in the biological samples.
7 . The method of claim 1 , wherein the biological sample is selected from the group consisting of: skin biopsies, kidney biopsies, whole blood, serum, and urine.
8 . The method of claim 7 , wherein the biological sample is whole blood.
9 . The method of claim 1 , wherein the one or more cytotoxic cell markers comprises the percentage of natural killer cells.
10 . The method of claim 1 , wherein one or more cytotoxic cell markers comprises the expression level of the one or more cytotoxic cell-associated transcriptional genes.
11 . The method of claim 1 , wherein the one or more IFN-I markers comprises the expression level of Interferon alpha.
12 . The method of claim 1 , wherein the one or more IFN-I markers comprises the expression level of one or more IFN-I inducible genes.
13 . The method of claim 1 , wherein the one or more cytotoxic cell marker comprises percentage of natural killer cells and the one or more IFN-I markers comprises the expression level of Interferon alpha.
14 . The method of claim 1 , wherein the patients are treated by administering the anti-IL-12/IL-23p40 antibody and an IFN-I inhibitor.
15 . The method of claim 14 , wherein the IFN-I inhibitor is selected from the group consisting of: an anti-IFN alpha antibody, an anti IFN-I receptor antibody, inhibitors of Toll-Like Receptors (TLRs) 7, 8, and 9, agents that deplete or inhibit plasmacytoid dendritic cell function, and agents that inhibit Janus Kinase 1 (JAK1).
16 . The method of claim 15 , wherein the IFN-I inhibitor is selected from the group consisting of: the anti-IFN alpha antibody sifalimumab, the anti-IFN alpha antibody JNJ-55920839 (CNTO 6358) and the anti IFN-I receptor antibody anifrolumab.
17 . The method of claim 1 , wherein the anti-IL-12/IL-23p40 antibody is administered with an initial intravenous (IV) dose at week 0, followed by administrations of a subcutaneous (SC) dose every 8 weeks (q8w) or wherein the antibody is administered as an initial subcutaneous (SC) dose, followed by administrations of a SC dose every 8 weeks (q8w).
18 . The method of claim 17 , wherein the initial IV dose is 6.0 mg/kg±1.5 mg/kg and the SC dose is 90 mg.
19 . The method of claim 18 , wherein the initial IV dose is 260 mg for patients with body weight≥35 kg and ≤55 kg, 390 mg for patients with body weight>55 kg and ≤85 kg, and 520 mg for patients with body weight>85 kg.
20 . A method for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, the method comprising:
a. determining the expression level of one or more cytotoxic cell-associated transcriptional genes or one or more IFN-1 inducible genes in biological samples from the patients; wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GPR56, GZMH, GZMK, KLRC3, KLRD1, KLRG1, LOC387895, MYBL1, NKG7, PRF1, TARP, TRGC2, XRRA1, GSTM4, CXCR3, GZMA, and TRGV2; and wherein the one or more IFN-I inducible genes is selected from the group consisting of: BST2, CARD17, CMPK2, DDX58, DDX60, DHX58, EIF2AK2, EPSTI1, FBXO39, HERC5, HERC6, IFIT1, IFIT2, IFIT3, IRF7, LAP3, LOC100133669, OAS3, OASL, OTOF, PLSCR1, RSAD2, RTP4, SAMD9L, SIGLEC1, SPATS2L, TIMM10, USP18, ISG15, IFI27, IFI44, IFI44L, and ZBP1; b. selecting the individual patients who are predicted to have an increased likelihood of having a positive response to the treatment with the anti-IL-12/IL-23p40 antibody, wherein the predicted increased likelihood of having a positive response to the treatment with the anti-IL-12/IL-23p40 antibody is determined with a logistic regression model of the formula:
min
?
-
[
1
N
∑
?
y
i
(
β
o
+
β
T
x
?
)
-
log
(
1
+
?
]
+
λ
[
(
1
-
α
)
2
β
2
2
+
α
β
1
]
?
indicates text missing or illegible when filed
wherein N is the number of patients used to learn the model, x i is a vector of the centered gene expression data of patient i, y i is the response outcome for patient i (responder/non-responder), λ controls the total penalty weight, α controls the elastic-net penalty weight: form lasso (α=1) to ridge (α=0), and α, λ are optimized using grid search based on best training accuracy; and,
wherein after β 0 , β parameters are determined a response probability is determined by the formula:
P
(
?
)
=
1
1
+
?
?
indicates text missing or illegible when filed
and response prediction is determined with a threshold of 0.5 using the formula:
Response
(
x
?
)
=
{
responder
,
if
P
(
x
)
≥
threshlod
non
-
responder
,
else
;
?
indicates text missing or illegible when filed
and
c. treating the selected patients by administering the anti-IL-12/IL-23p40 antibody.
21 . A method for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, the method comprising:
a. determining the expression level of one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b. calculating the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes in the biological samples from the patients; c. comparing the calculated mean expression levels to the expression levels in individual patients for the one or more cytotoxic cell-associated transcriptional genes; d. determining if the individual patients have higher expression levels or lower expression levels compared to the mean expression levels of the one or more cytotoxic cell-associated transcriptional genes; e. selecting the individual patients from the group consisting of: individual patients with higher expression levels of the one or more cytotoxic cell-associated transcriptional genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment with an anti-IL-12/IL-23p40 antibody; and f. treating the selected patients by administering the anti-IL-12/IL-23p40 antibody; wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GPR56, GZMK, XRRA1, GSTM4, KLRC3, KLRD1, KLRG1, LOC387895, MYBL1, NKG7, PRF1, TARP, TRGC2, CXCR3, GZMA, and TRGV2.
22 . The method of claim 21 , wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GZMH, GZMK, NKG7 and PRF1.
23 . A method for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody, the method comprising:
a. determining the expression level of one or more cytotoxic cell-associated transcriptional genes in biological samples from the patients; b. comparing the expression levels in individual patients to the average expression levels in healthy controls for the one or more cytotoxic cell-associated transcriptional genes; c. determining if the individual patients have lower expression levels compared to the average expression levels in healthy controls for the one or more cytotoxic cell-associated transcriptional genes; d. selecting the individual patients that do not have lower expression levels compared to the average expression levels in healthy controls for the one or more cytotoxic cell-associated transcriptional genes, wherein the selected patients are predicted to have an increased likelihood of having a positive response to the treatment with an anti-IL-12/1L-23p40 antibody; and e. treating the selected patients by administering the anti-IL-12/IL-23p40 antibody; wherein the one or more cytotoxic cell-associated transcriptional genes is selected from the group consisting of: FCRL6, FGFBP2, GNLY, GPR56, GZMK, XRRA1, GSTM4, KLRC3, KLRD1, KLRG1, LOC387895, MYBL1, NKG7, PRF1, TARP, TRGC2, CXCR3, GZMA, and TRGV2.
24 . The method of claim 23 , wherein the lower expression levels of the one or more cytotoxic cell-associated transcriptional genes compared to the average expression levels in healthy controls is a Gene Set Variation Analysis (GSVA) Enrichment Score (ES) of the one or more cytotoxic cell-associated transcriptional genes 0.4 below the median of the healthy controls.Join the waitlist — get patent alerts
Track US2023279097A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.